ClinicalTrials.gg
CompletedNCT02957682Updated May 7, 2021Results posted

Evaluating Effect of the Study Drug Praluent (Alirocumab) on Neurocognitive Function When Compared to Placebo

A Phase 4 interventional study of Praluent (Alirocumab) and Placebo in Hypercholesterolemia, sponsored by Regeneron Pharmaceuticals. Completed at 189 sites in 9 countries. Open to participants aged 40 Years to 85 Years. Per ClinicalTrials.gov, last updated 2021-05-07.

Sponsored by Regeneron Pharmaceuticals · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
2,176
Allocation
Randomized
Ages
40 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 43 studies testing alirocumab in Hypercholesterolemia — 1 open to participants now, 2 under way, none of them phase 3. alirocumab · Hypercholesterolemia.

Enrollment
2nd of 43
2,176 · median 107
Started
2016
with 4 others
Phase 4
5 of 43
1 open now
Registered
34th of 43
by date
Lead sponsor
11 of 43
Regeneron Pharmaceuticals

Among the 43 studies testing alirocumab in Hypercholesterolemia, this one is the 2nd largest by enrollment, is one of 5 that started in 2016, is one of 5 in phase 4, and was the 34th registered.

Hypercholesterolemia

1,177 studies on the registry are indexed under Hypercholesterolemia; 95 are open to participants now.

Browse Hypercholesterolemia studies →

Open to participants now

1 of the 43 studies testing alirocumab in Hypercholesterolemia is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About alirocumab

alirocumab: first FDA approval 2015 (PRALUENT), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 55 Hypercholesterolemia studies recruiting now, 23 (42%) set no upper age limit and 20 (36%) stop at 75 or younger; 9 take children under 18; 11 take healthy volunteers.

This study: 40 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 43 studies testing alirocumab in Hypercholesterolemia, or all of them as a file.
02

Study summary

The main purpose of this study is to evaluate the effect on mental state (known as "neurocognitive function") with use of Praluent.

03

Conditions studied

  • Hypercholesterolemia

Keywords

  • Hyperlipidemias
  • Dyslipidemias
  • Lipid Metabolism Disorders
04

Who can participate

Ages eligible
40 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Men and women ≥ age 40 years and ≤ age 85 years
  • Patients with heterozygous familial hypercholesterolemia (heFH) or with non-familial hypercholesterolemia (non-FH) patients at high or very high cardiovascular risk
  • Patients with history of coronary heart disease (CHD) not having adequate control of their hypercholesterolemia with LDL-C ≥70 mg/dL, or all other patients with LDL-C ≥100 mg/dL and be on maximally-tolerated dose of statin (unless they are statin-intolerant)
  • Patients must have successfully completed the Motor Screening Task
  • Patients must be willing and able to comply with clinic visits and study related procedures
  • Patients must provide signed

Key Exclusion Criteria:

  • Patients with known Alzheimer's disease or other dementia, schizophrenia, bipolar disorder, severe depression, cognitive impairment, or patients with a sleep disorder requiring daily pharmacological treatment
  • Recent (within 3 months prior to the screening visit) myocardial infarction, unstable angina leading to hospitalization, coronary artery bypass graft surgery, percutaneous coronary intervention, uncontrolled cardiac arrhythmia, carotid surgery or stenting, stroke, , carotid revascularization, endovascular procedure or surgical intervention for peripheral vascular disease
  • Certain laboratory findings obtained during the screening visit as defined in the protocol
  • Any condition or situation, including other significant mental or neurological disorders that, in the investigator's opinion, may confound the study results, or may interfere significantly with the patient's participation in the study
  • Pregnant or breastfeeding women
  • A positive (HIV) test

NOTE: Other protocol defined Inclusion/Exclusion Criteria apply

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
2,176 participants (actual)

Study arms

  • Experimental
    Group 1

    Praluent Regimen - Administration through subcutaneous injection

    Drug: Praluent (Alirocumab)

  • Experimental
    Group 2

    Placebo matching Praluent - Administration through subcutaneous injection

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Cambridge Neuropsychological Test Automated Battery (CANTAB) Cognitive Domain Spatial Working Memory (SWM) Strategy Z-Score at Week 96

    CANTAB SWM task assessed cognitive domain of executive function. Colored boxes were shown on a screen. A token was hidden in one of the boxes (never same box twice). Instructions were to touch boxes to search for token until number of tokens found equaled number of boxes. SWM strategy index represents number of times a search began with a different box. Z-score represents standardized measure of how far an individual deviated from study cohort average at baseline. A higher Z-score reflects better performance.

    Time frame: Week 96

Secondary outcomes

  1. Change From Baseline in CANTAB Cognitive Domain SWM Strategy Raw Score at Week 96

    CANTAB SWM task assessed cognitive domain of executive function. Colored boxes were shown on a screen. A token was hidden in one of the boxes (never same box twice). Instructions were to touch boxes to search for token until number of tokens found equaled number of boxes. SWM strategy index represents number of times a search began with a different box. Lower change from baseline raw scores reflect better SWM performance (i.e. less impairment).

    Time frame: Week 96

  2. Percent Change From Baseline in Calculated Low-density Lipoprotein Cholesterol (LDL-C) at Week 12, 24, 48, 72, and 96

    Percent change from baseline in calculated LDL-C at Week 12, 24, 48, 72, and 96 was reported. LDL-C was measured using conventional units milligram per deciliter (mg/dL).

    Time frame: Week 12, 24, 48, 72, and 96

  3. Percent Change From Baseline in Apolipoprotein (Apo) B at Week 12, 24, 48, 72, and 96

    Percent change from baseline in Apo B at Week 12, 24, 48, 72, and 96 was reported. Apo B was measured using conventional units mg/dL.

    Time frame: Week 12, 24, 48, 72, and 96

  4. Percent Change From Baseline in Non-High-Density Lipoprotein Cholesterol (Non-HDL-C) at Week 12, 24, 48, 72, and 96

    Percent change from baseline in non-HDL-C at Week 12, 24, 48, 72, and 96 was reported. Non-HDL-C was measured using conventional units mg/dL.

    Time frame: Week 12, 24, 48, 72, and 96

  5. Percent Change From Baseline in Total Cholesterol (Total-C) at Week 12, 24, 48, 72, and 96

    Percent change from baseline in calculated Total-C at Week 12, 24, 48, 72, and 96 was reported. Total-C was measured using conventional units mg/dL.

    Time frame: Week 12, 24, 48, 72, and 96

  6. Percent Change From Baseline in Lipoprotein a [Lp(a)] at Week 12, 24, 48, 72, and 96

    Percent change from baseline in Lp(a) at Week 12, 24, 48, 72, and 96 was reported. Lp(a) was measured using conventional units mg/dL.

    Time frame: Week 12, 24, 48, 72, and 96

  7. Percent Change From Baseline in High-Density Lipoprotein Cholesterol (HDL-C) at Week 12, 24, 48, 72, and 96

    Percent change from baseline in HDL-C at Week 12, 24, 48, 72, and 96 was reported. HDL-C was measured using conventional units mg/dL.

    Time frame: Week 12, 24, 48, 72, and 96

  8. Percent Change From Baseline in Triglycerides (TG) at Week 12, 24, 48, 72, and 96

    Percent change from baseline in TG at Week 12, 24, 48, 72, and 96 was reported. TG was measured using conventional units mg/dL.

    Time frame: Week 12, 24, 48, 72, and 96

  9. Percent Change From Baseline in Apolipoprotein (Apo) A-1 at Week 12, 24, 48, 72, and 96

    Percent change from baseline in Apo A-1 at Week 12, 24, 48, 72, and 96 was reported. Apo A-1 was measured using conventional units mg/dL.

    Time frame: Week 12, 24, 48, 72, and 96

  10. Percentage of Participants Who Reached Low Density Lipoprotein Cholesterol (LDL-C) Level Less Than (<) 70 mg/dL (1.81 Millimoles Per Liter [mmol/L]) at Week 12, 24, 48, 72, and 96

    Percentage of participants who reached LDL-C level \< 70 mg/dL (1.81 mmol/L) at Week 12, 24, 48, 72, and 96 were reported.

    Time frame: Week 12, 24, 48, 72, and 96

  11. Percentage of Participants Who Reached Low Density Lipoprotein Cholesterol (LDL-C) Level Less Than (<) 50 mg/dL (1.29 mmol/L) at Week 12, 24, 48, 72, and 96

    Percentage of participants who reached LDL-C level \< 50 mg/dL (1.29 mmol/L) at Week 12, 24, 48, 72, and 96 were reported.

    Time frame: Week 12, 24, 48, 72, and 96

  12. Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious TEAEs

    An Adverse Event (AE) was any untoward medical occurrence in a participant administered a study drug which may or may not have a causal relationship with the study drug. TEAE was defined as AEs that developed or worsened/became serious during on-treatment period (time from the first double-blind study treatment injection up to 70 days after the last double-blind study treatment injection). A serious adverse event (SAE) was defined as any untoward medical occurrence that resulted in any of the following outcomes: death, life-threatening, required initial or prolonged in-participant hospitalization, persistent or significant disability/incapacity, congenital anomaly/birth defect, or considered as medically important event. Any TEAE included participants with both serious and non-serious AEs.

    Time frame: Up to Week 96

07

Results

Posted May 7, 2021

Participant flow

A total of 2176 participants were randomized across 169 sites in Bulgaria, Chile, Estonia, Japan, Mexico, Russian Federation, South Africa, Ukraine, and the United States

Participant flow — Overall Study
MilestonePlaceboAlirocumab 75 Q2W/Up150 Q2W
Started10881088
Randomized and treated10851086
Completed890919
Not completed198169
Withdrew: Adverse event6467
Withdrew: Poor compliance to protocol3026
Withdrew: Physician decision44
Withdrew: Study terminated by sponsor43
Withdrew: Subject moved1016
Withdrew: Withdrawal by subject6433
Withdrew: Related to imp administration36
Withdrew: Non-disclosed1612
Withdrew: Discontinued after randomization and prior to any treatment32

Outcome measures

PrimaryChange From Baseline in Cambridge Neuropsychological Test Automated Battery (CANTAB) Cognitive Domain Spatial Working Memory (SWM) Strategy Z-Score at Week 96

CANTAB SWM task assessed cognitive domain of executive function. Colored boxes were shown on a screen. A token was hidden in one of the boxes (never same box twice). Instructions were to touch boxes to search for token until number of tokens found equaled number of boxes. SWM strategy index represents number of times a search began with a different box. Z-score represents standardized measure of how far an individual deviated from study cohort average at baseline. A higher Z-score reflects better performance.

Time frame:
Week 96
Reported as:
Least squares mean · Z-score
Change From Baseline in Cambridge Neuropsychological Test Automated Battery (CANTAB) Cognitive Domain Spatial Working Memory (SWM) Strategy Z-Score at Week 96
Z-scorePlaceboAlirocumab 75 Q2W/Up150 Q2W
Change From Baseline in Cambridge Neuropsychological Test Automated Battery (CANTAB) Cognitive Domain Spatial Working Memory (SWM) Strategy Z-Score at Week 96-0.180 ± 0.027-0.200 ± 0.027
Statistical analysis
  • Placebo vs Alirocumab 75 Q2W/Up150 Q2W · Mixed-effect Model Repeated Measures · p = 0.6055 (P-value was taken from mixed-effect model with repeated measures (MMRM) analysis.) · Least square (ls) mean difference: -0.020 · 95% CI -0.094 to 0.055Model: fixed categorical effects of treatment group, randomization strata as per IVRS, time point, treatment-by-time point, strata-by-time point, continuous fixed covariates of baseline SWMS raw score value, baseline value by time-point interaction.
SecondaryChange From Baseline in CANTAB Cognitive Domain SWM Strategy Raw Score at Week 96

CANTAB SWM task assessed cognitive domain of executive function. Colored boxes were shown on a screen. A token was hidden in one of the boxes (never same box twice). Instructions were to touch boxes to search for token until number of tokens found equaled number of boxes. SWM strategy index represents number of times a search began with a different box. Lower change from baseline raw scores reflect better SWM performance (i.e. less impairment).

Time frame:
Week 96
Reported as:
Mean · Units on a Scale
Change From Baseline in CANTAB Cognitive Domain SWM Strategy Raw Score at Week 96
Units on a ScalePlaceboAlirocumab 75 Q2W/Up150 Q2W
Change From Baseline in CANTAB Cognitive Domain SWM Strategy Raw Score at Week 96-0.9 ± 4.49-1.0 ± 4.31
SecondaryPercent Change From Baseline in Calculated Low-density Lipoprotein Cholesterol (LDL-C) at Week 12, 24, 48, 72, and 96

Percent change from baseline in calculated LDL-C at Week 12, 24, 48, 72, and 96 was reported. LDL-C was measured using conventional units milligram per deciliter (mg/dL).

Time frame:
Week 12, 24, 48, 72, and 96
Reported as:
Least squares mean · Percent Change
Percent Change From Baseline in Calculated Low-density Lipoprotein Cholesterol (LDL-C) at Week 12, 24, 48, 72, and 96
Percent ChangePlaceboAlirocumab 75 Q2W/Up150 Q2W
Percent change at Week 120.6 ± 1.0-49.6 ± 0.9
Percent change at Week 243.0 ± 1.0-54.2 ± 1.0
Percent change at Week 482.8 ± 1.1-51.4 ± 1.1
Percent change at Week 722.4 ± 1.2-50.4 ± 1.2
Percent change at Week 964.0 ± 1.3-46.2 ± 1.3
SecondaryPercent Change From Baseline in Apolipoprotein (Apo) B at Week 12, 24, 48, 72, and 96

Percent change from baseline in Apo B at Week 12, 24, 48, 72, and 96 was reported. Apo B was measured using conventional units mg/dL.

Time frame:
Week 12, 24, 48, 72, and 96
Reported as:
Least squares mean · Percent Change
Percent Change From Baseline in Apolipoprotein (Apo) B at Week 12, 24, 48, 72, and 96
Percent ChangePlaceboAlirocumab 75 Q2W/Up150 Q2W
Percent change at Week 120.8 ± 0.7-36.7 ± 0.7
Percent change at Week 242.1 ± 0.8-40.9 ± 0.8
Percent change at Week 481.1 ± 0.8-39.0 ± 0.8
Percent change at Week 720.2 ± 0.9-39.1 ± 0.8
Percent change at Week 961.4 ± 0.9-36.4 ± 0.9
SecondaryPercent Change From Baseline in Non-High-Density Lipoprotein Cholesterol (Non-HDL-C) at Week 12, 24, 48, 72, and 96

Percent change from baseline in non-HDL-C at Week 12, 24, 48, 72, and 96 was reported. Non-HDL-C was measured using conventional units mg/dL.

Time frame:
Week 12, 24, 48, 72, and 96
Reported as:
Least squares mean · Percent Change
Percent Change From Baseline in Non-High-Density Lipoprotein Cholesterol (Non-HDL-C) at Week 12, 24, 48, 72, and 96
Percent ChangePlaceboAlirocumab 75 Q2W/Up150 Q2W
Percent change at Week 120.7 ± 0.8-40.4 ± 0.8
Percent change at Week 242.2 ± 0.9-44.0 ± 0.9
Percent change at Week 481.7 ± 0.9-41.1 ± 0.9
Percent change at Week 721.7 ± 1.0-40.6 ± 1.0
Percent change at Week 962.5 ± 1.1-37.0 ± 1.1
SecondaryPercent Change From Baseline in Total Cholesterol (Total-C) at Week 12, 24, 48, 72, and 96

Percent change from baseline in calculated Total-C at Week 12, 24, 48, 72, and 96 was reported. Total-C was measured using conventional units mg/dL.

Time frame:
Week 12, 24, 48, 72, and 96
Reported as:
Least squares mean · Percent Change
Percent Change From Baseline in Total Cholesterol (Total-C) at Week 12, 24, 48, 72, and 96
Percent ChangePlaceboAlirocumab 75 Q2W/Up150 Q2W
Percent change at Week 12-0.3 ± 0.6-29.6 ± 0.6
Percent change at Week 241.5 ± 0.6-31.8 ± 0.6
Percent change at Week 481.1 ± 0.7-29.6 ± 0.7
Percent change at Week 721.1 ± 0.7-29.0 ± 0.7
Percent change at Week 961.8 ± 0.7-26.5 ± 0.7
SecondaryPercent Change From Baseline in Lipoprotein a [Lp(a)] at Week 12, 24, 48, 72, and 96

Percent change from baseline in Lp(a) at Week 12, 24, 48, 72, and 96 was reported. Lp(a) was measured using conventional units mg/dL.

Time frame:
Week 12, 24, 48, 72, and 96
Reported as:
Least squares mean · Percent Change
Percent Change From Baseline in Lipoprotein a [Lp(a)] at Week 12, 24, 48, 72, and 96
Percent ChangePlaceboAlirocumab 75 Q2W/Up150 Q2W
Percent change at Week 12-3.3 ± 0.8-22.4 ± 0.8
Percent change at Week 24-0.5 ± 0.9-24.7 ± 0.9
Percent change at Week 48-1.4 ± 1.0-24.3 ± 1.0
Percent change at Week 72-1.7 ± 1.0-25.1 ± 1.0
Percent change at Week 964.8 ± 1.1-17.7 ± 1.1
SecondaryPercent Change From Baseline in High-Density Lipoprotein Cholesterol (HDL-C) at Week 12, 24, 48, 72, and 96

Percent change from baseline in HDL-C at Week 12, 24, 48, 72, and 96 was reported. HDL-C was measured using conventional units mg/dL.

Time frame:
Week 12, 24, 48, 72, and 96
Reported as:
Least squares mean · Percent Change
Percent Change From Baseline in High-Density Lipoprotein Cholesterol (HDL-C) at Week 12, 24, 48, 72, and 96
Percent ChangePlaceboAlirocumab 75 Q2W/Up150 Q2W
Percent change at Week 120.6 ± 0.55.9 ± 0.5
Percent change at Week 243.8 ± 0.69.0 ± 0.6
Percent change at Week 483.8 ± 0.69.2 ± 0.6
Percent change at Week 724.4 ± 0.710.3 ± 0.6
Percent change at Week 965.5 ± 0.710.8 ± 0.7
SecondaryPercent Change From Baseline in Triglycerides (TG) at Week 12, 24, 48, 72, and 96

Percent change from baseline in TG at Week 12, 24, 48, 72, and 96 was reported. TG was measured using conventional units mg/dL.

Time frame:
Week 12, 24, 48, 72, and 96
Reported as:
Least squares mean · Percent Change
Percent Change From Baseline in Triglycerides (TG) at Week 12, 24, 48, 72, and 96
Percent ChangePlaceboAlirocumab 75 Q2W/Up150 Q2W
Percent change at Week 120.7 ± 1.0-11.0 ± 1.0
Percent change at Week 24-1.8 ± 1.0-12.9 ± 1.0
Percent change at Week 48-1.8 ± 1.1-11.3 ± 1.1
Percent change at Week 72-2.1 ± 1.1-12.3 ± 1.1
Percent change at Week 96-2.7 ± 1.1-11.9 ± 1.1
SecondaryPercent Change From Baseline in Apolipoprotein (Apo) A-1 at Week 12, 24, 48, 72, and 96

Percent change from baseline in Apo A-1 at Week 12, 24, 48, 72, and 96 was reported. Apo A-1 was measured using conventional units mg/dL.

Time frame:
Week 12, 24, 48, 72, and 96
Reported as:
Least squares mean · Percent Change
Percent Change From Baseline in Apolipoprotein (Apo) A-1 at Week 12, 24, 48, 72, and 96
Percent ChangePlaceboAlirocumab 75 Q2W/Up150 Q2W
Percent change at Week 12-1.3 ± 0.41.7 ± 0.4
Percent change at Week 242.9 ± 0.46.1 ± 0.4
Percent change at Week 484.7 ± 0.47.7 ± 0.4
Percent change at Week 724.4 ± 0.47.8 ± 0.4
Percent change at Week 964.2 ± 0.47.5 ± 0.4
SecondaryPercentage of Participants Who Reached Low Density Lipoprotein Cholesterol (LDL-C) Level Less Than (<) 70 mg/dL (1.81 Millimoles Per Liter [mmol/L]) at Week 12, 24, 48, 72, and 96

Percentage of participants who reached LDL-C level \< 70 mg/dL (1.81 mmol/L) at Week 12, 24, 48, 72, and 96 were reported.

Time frame:
Week 12, 24, 48, 72, and 96
Reported as:
Number · Percentage of Participants
Percentage of Participants Who Reached Low Density Lipoprotein Cholesterol (LDL-C) Level Less Than (<) 70 mg/dL (1.81 Millimoles Per Liter [mmol/L]) at Week 12, 24, 48, 72, and 96
Percentage of ParticipantsPlaceboAlirocumab 75 Q2W/Up150 Q2W
Week 1210.369.4
Week 248.474.7
Week 4810.771.4
Week 7211.369.7
Week 9610.764.5
SecondaryPercentage of Participants Who Reached Low Density Lipoprotein Cholesterol (LDL-C) Level Less Than (<) 50 mg/dL (1.29 mmol/L) at Week 12, 24, 48, 72, and 96

Percentage of participants who reached LDL-C level \< 50 mg/dL (1.29 mmol/L) at Week 12, 24, 48, 72, and 96 were reported.

Time frame:
Week 12, 24, 48, 72, and 96
Reported as:
Number · Percentage of Participants
Percentage of Participants Who Reached Low Density Lipoprotein Cholesterol (LDL-C) Level Less Than (<) 50 mg/dL (1.29 mmol/L) at Week 12, 24, 48, 72, and 96
Percentage of ParticipantsPlaceboAlirocumab 75 Q2W/Up150 Q2W
Week 121.745.6
Week 242.056.9
Week 482.151.3
Week 722.552.1
Week 962.446.4
SecondaryNumber of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious TEAEs

An Adverse Event (AE) was any untoward medical occurrence in a participant administered a study drug which may or may not have a causal relationship with the study drug. TEAE was defined as AEs that developed or worsened/became serious during on-treatment period (time from the first double-blind study treatment injection up to 70 days after the last double-blind study treatment injection). A serious adverse event (SAE) was defined as any untoward medical occurrence that resulted in any of the following outcomes: death, life-threatening, required initial or prolonged in-participant hospitalization, persistent or significant disability/incapacity, congenital anomaly/birth defect, or considered as medically important event. Any TEAE included participants with both serious and non-serious AEs.

Time frame:
Up to Week 96
Reported as:
Count of participants · Participants
Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious TEAEs
ParticipantsPlaceboAlirocumab 75 Q2W/Up150 Q2W
Participants with any TEAEs857866
Participants with any Serious TEAEs216189
Participants with any TEAE leading to death1713
Participants with any TEAE leading to permanent treatment discontinuation5964

Adverse events

Collected over All Adverse Events (AEs) were collected from signature of the informed consent form up to the end of study (Week 96) regardless of seriousness or relationship to investigational product (IP).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo24/1,084 (2.2%)216/1,084 (19.9%)387/1,084 (35.7%)
Alirocumab 75 Q2W/Up150 Q2W17/1,087 (1.6%)189/1,087 (17.4%)366/1,087 (33.7%)
Most frequent serious events
Showing 10 of 271
Most frequent serious events
EventPlaceboAlirocumab 75 Q2W/Up150 Q2W
Angina unstableCardiac disorders16/108414/1087
Atrial fibrillationCardiac disorders13/10845/1087
Angina pectorisCardiac disorders10/108411/1087
Coronary artery diseaseCardiac disorders8/10846/1087
Acute myocardial infarctionCardiac disorders7/10845/1087
HypertensionVascular disorders7/10846/1087
OsteoarthritisMusculoskeletal and connective tissue disorders2/10846/1087
PneumoniaInfections and infestations5/10844/1087
Ischaemic strokeNervous system disorders5/10844/1087
Acute coronary syndromeCardiac disorders4/10841/1087
Most frequent other events
Most frequent other events
EventPlaceboAlirocumab 75 Q2W/Up150 Q2W
NasopharyngitisInfections and infestations89/108482/1087
HeadacheNervous system disorders85/108471/1087
HypertensionVascular disorders73/108464/1087
Back painMusculoskeletal and connective tissue disorders71/108460/1087
InfluenzaInfections and infestations69/108463/1087
BronchitisInfections and infestations65/108460/1087
Urinary tract infectionInfections and infestations46/108461/1087

Baseline characteristics

Safety population (SAF) included all participants randomized and exposed to at least one dose of study drug, regardless of the amount of treatment administered.

Age, Continuous
Age, Continuous(Years)PlaceboAlirocumab 75 Q2W/Up150 Q2WTotal
Mean62.7 ± 9.0262.6 ± 8.8862.6 ± 8.95
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboAlirocumab 75 Q2W/Up150 Q2WTotal
Female459448907
Male6256391264
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)PlaceboAlirocumab 75 Q2W/Up150 Q2WTotal
Hispanic or Latino137142279
Not Hispanic or Latino9459431888
Unknown or Not Reported224
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)PlaceboAlirocumab 75 Q2W/Up150 Q2WTotal
White8888861774
Black or African American8677163
Asian192847
American Indian or Alaska Native111627
Native Hawaiian or Other Pacific Islander000
Other8080160
CANTAB Cognitive Domain Spatial Working Memory (SWM) Strategy Raw Score
CANTAB Cognitive Domain Spatial Working Memory (SWM) Strategy Raw Score(Units on a Scale)PlaceboAlirocumab 75 Q2W/Up150 Q2WTotal
Mean15.9 ± 5.0316.05 ± 5.1116.0 ± 5.07
08

Study locations

189 sites
  • Regeneron Study Site
    Auburn, Alabama 36830, United States
  • Regeneron Study Site
    Birmingham, Alabama 35209, United States
  • Regeneron Study Site
    Mobile, Alabama 36608, United States
  • Regeneron Study Site
    Beverly Hills, California 90210, United States
  • Regeneron Study Site
    Los Gatos, California 95032, United States
  • Regeneron Study Site
    North Hollywood, California 91606, United States
  • Regeneron Study Site
    Port Hueneme, California 93041, United States
  • Regeneron Study Site
    Westminster, California 92683, United States
  • Regeneron Study Site 1
    Aurora, Colorado 80012, United States
  • Regeneron Study Site 2
    Aurora, Colorado 80012, United States
  • Regeneron Study Site
    Colorado Springs, Colorado 80906, United States
  • Regeneron Study Site
    Lake Worth, Florida 33461, United States
  • Regeneron Study Site
    Lake Worth, Florida 33462, United States
  • Regeneron Study Site
    Miami Springs, Florida 33166, United States
  • Regeneron Study Site
    Covington, Georgia 30014, United States
  • Regeneron Study Site
    Champaign, Illinois 61822, United States
  • Regeneron Study Site
    Chicago, Illinois 60602, United States
  • Regeneron Study Site
    Chicago, Illinois 60640, United States
  • Regeneron Study Site
    Rock Island, Illinois 61201, United States
  • Regeneron Study Site
    Evansville, Indiana 47714, United States
  • Regeneron Study Site
    Indianapolis, Indiana 46237, United States
  • Regeneron Study Site
    Ames, Iowa 50010-3014, United States
  • Regeneron Study Site
    Iowa City, Iowa 52242, United States
  • Regeneron Study Site
    Waterloo, Iowa 50702, United States
  • Regeneron Study Site
    Hutchinson, Kansas 67502, United States
  • Regeneron Study Site
    Newton, Kansas 67114, United States
  • Regeneron Study Site
    Overland Park, Kansas 66209, United States
  • Regeneron Study Site
    Louisville, Kentucky 40213, United States
  • Regeneron Study Site
    Bangor, Maine 04401, United States
  • Regeneron Study Site
    Baltimore, Maryland 21229, United States
  • Regeneron Study Site
    Oxon Hill, Maryland 20745, United States
  • Regeneron Study Site
    Minneapolis, Minnesota 55407, United States
  • Regeneron Study Site
    Olive Branch, Mississippi 38654, United States
  • Regeneron Study Site
    Washington, Missouri 63090, United States
  • Regeneron Study Site
    Buffalo, New York 14215, United States
  • Regeneron Study Site
    New Hyde Park, New York 11042, United States
  • Regeneron Study Site
    Cary, North Carolina 27518, United States
  • Regeneron Study Site
    Charlotte, North Carolina 28209, United States
  • Regeneron Study Site
    Charlotte, North Carolina 28277, United States
  • Regeneron Study Site
    Greensboro, North Carolina 27401, United States
  • Regeneron Study Site
    Hickory, North Carolina 28601, United States
  • Regeneron Study Site
    High Point, North Carolina 27262, United States
  • Regeneron Study Site
    Raleigh, North Carolina 27609, United States
  • Regeneron Study Site
    Rocky Mount, North Carolina 27804, United States
  • Regeneron Study Site
    Salisbury, North Carolina 28144, United States
  • Regeneron Study Site
    Statesville, North Carolina 28625, United States
  • Regeneron Study Site
    Wilmington, North Carolina 28401, United States
  • Regeneron Study Site
    Winston-Salem, North Carolina 27103, United States
  • Regeneron Study Site
    Cincinnati, Ohio 45219, United States
  • Regeneron Study Site
    Cleveland, Ohio 44122, United States
  • Regeneron Study Site
    Dayton, Ohio 45414, United States
  • Regeneron Study Site
    Duncansville, Pennsylvania 16635, United States
  • Regeneron Study Site
    Charleston, South Carolina 29407, United States
  • Regeneron Study Site
    Greenville, South Carolina 29485, United States
  • Regeneron Study Site
    Summerville, South Carolina 29615, United States
  • Regeneron Study Site
    Rapid City, South Dakota 57701, United States
  • Regeneron Study Site
    Bristol, Tennessee 37620, United States
  • Regeneron Study Site
    Knoxville, Tennessee 37760, United States
  • Regeneron Study Site
    Knoxville, Tennessee 37912, United States
  • Regeneron Study Site
    Knoxville, Tennessee 37938, United States
  • Regeneron Study Site
    Powell, Tennessee 37849, United States
  • Regeneron Study Site
    Dallas, Texas 75231, United States
  • Regeneron Study Site
    Houston, Texas 77002, United States
  • Regeneron Study Site
    Houston, Texas 77027, United States
  • Regeneron Study Site
    Schertz, Texas 78154, United States
  • Regeneron Study Site
    Shavano Park, Texas 78231, United States
  • Regeneron Study Site
    Falls Church, Virginia 22601, United States
  • Regeneron Study Site
    Winchester, Virginia 22042, United States
  • Regeneron Study Site
    Burien, Washington 98166, United States
  • Regeneron Study Site
    Everett, Washington 98405, United States
  • Regeneron Study Site
    Tacoma, Washington 98405, United States
  • Regeneron Study Site
    Walla Walla, Washington 99362, United States
  • Regeneron Study Site
    Manitowoc, Wisconsin 54220, United States
  • Regeneron Study Site
    Pleven, 5800, Bulgaria
  • Regeneron Study Site
    Plovdiv, 4000, Bulgaria
  • Regeneron Study Site
    Plovdiv, 4002, Bulgaria
  • Regeneron Study Site
    Sofia, 1309, Bulgaria
  • Regeneron Study Site
    Sofia, 1407, Bulgaria
  • Regeneron Study Site
    Sofia, 1784, Bulgaria
  • Regeneron Study Site
    Stara Zagora, 6000, Bulgaria
  • Regeneron Study Site 1
    Varna, 9000, Bulgaria
  • Regeneron Study Site 2
    Varna, 9000, Bulgaria
  • Regeneron Study Site
    Osorno, 5290000, Chile
  • Regeneron Study Site
    San Miguel, 8910259, Chile
  • Regeneron Study Site
    Santiago, 7500710, Chile
  • Regeneron Study Site
    Santiago, 8207257, Chile
  • Regeneron Study Site
    Santiago, 8331143, Chile
  • Regeneron Study Site
    Santiago, Chile
  • Regeneron Study Site
    Temuco, 4781156, Chile
  • Regeneron Study Site
    Temuco, 4790869, Chile
  • Regeneron Study Site
    Viña del Mar, 2520997, Chile
  • Regeneron Study Site
    Paide, 72713, Estonia
  • Regeneron Study Site
    Tallinn, 10128, Estonia
  • Regeneron Study Site
    Tallinn, 10138, Estonia
  • Regeneron Study Site 1
    Tallinn, 10617, Estonia
  • Regeneron Study Site 2
    Tallinn, 10617, Estonia
  • Regeneron Study Site
    Tallinn, 11313, Estonia
  • Regeneron Study Site
    Tallinn, 11911, Estonia
  • Regeneron Study Site
    Tartu, 51014, Estonia
  • Regeneron Study Site
    Nishinomiya, Hogo 663-8501, Japan

Showing the first 100 of 189 sites across 9 countries. Choose a country and city above to see the rest.

09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2016 to primary completion in Mar 2020, 40 months.

Results were first posted in May 2021, 1 year 2 months after primary completion.

Of 40 phase 4 interventional studies under Hypercholesterolemia, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 26. This study's 40 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 28, 2016
First posted
Nov 8, 2016
StartActual
Nov 2, 2016
Primary completionActual
Mar 5, 2020
CompletionActual
Mar 5, 2020
Results first posted
May 7, 2021
Last update
May 7, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 7, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02957682
Collaborators
Sanofi
Responsible party
Sponsor
First posted
Nov 8, 2016
Start date
Nov 2, 2016
Primary completion
Mar 5, 2020
Completion
Mar 5, 2020
Results posted
May 7, 2021
Last update
May 7, 2021

Study contacts

Clinical Trial Management
study director · Regeneron Pharmaceuticals

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Alirocumab

Start the discussion